Economic impact of medication non-adherence by disease groups: a systematic review
Open accessThe DOI matches its Crossref record; 98 of the 113 references it cites were found in a registry or an index; 5 of the 59 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To determine the economic impact of medication non-adherence across multiple disease groups. DESIGN: Systematic review. EVIDENCE REVIEW: A comprehensive literature search was conducted in PubMed and Scopus in September 2017. Studies quantifying the cost of medication non-adherence in relation to economic impact were included. Relevant information was extracted and quality assessed using the Drummond checklist. RESULTS: Seventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included. Wide-scoping cost variations were reported, with lower levels of adherence generally associated with higher total costs. The annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44 190 (in 2015 US$). Costs attributed to 'all causes' non-adherence ranged from $5271 to $52 341. Medication possession ratio was the metric most used to calculate patient adherence, with varying cut-off points defining non-adherence. The main indicators used to measure the cost of non-adherence were total cost or total healthcare cost (83% of studies), pharmacy costs (70%), inpatient costs (46%), outpatient costs (50%), emergency department visit costs (27%), medical costs (29%) and hospitalisation costs (18%). Drummond quality assessment yielded 10 studies of high quality with all studies performing partial economic evaluations to varying extents. CONCLUSION: Medication non-adherence places a significant cost burden on healthcare systems. Current research assessing the economic impact of medication non-adherence is limited and of varying quality, failing to provide adaptable data to influence health policy. The correlation between increased non-adherence and higher disease prevalence should be used to inform policymakers to help circumvent avoidable costs to the healthcare system. Differences in methods make the comparison among studies challenging and an accurate estimation of true magnitude of the cost impossible. Standardisation of the metric measures used to estimate medication non-adherence and development of a streamlined approach to quantify costs is required. PROSPERO REGISTRATION NUMBER: CRD42015027338.
Overview
CoChat Summary
## TL;DR
This systematic review found that medication non-adherence is generally associated with higher healthcare costs across 14 disease groups, but the reported costs varied widely and could not be meaningfully pooled because of heterogeneity. Across 79 included studies, the adjusted annual disease-specific cost of non-adherence per person ranged from $949 to $44,190, and the authors concluded that standardised adherence and cost measures are needed.
## Key findings
- The review included 79 individual studies across 14 disease groups; search strategies retrieved 2768 records, 289 were full-text reviewed, and 79 were included.
- Reported annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44,190 (2015 US$); costs attributed to “all causes” non-adherence ranged from $5271 to $52,341.
- Across studies reporting total or total healthcare costs, 39 studies (49%) found non-adherence costs were greater than adherence costs, while 11 studies (15%) found the opposite.
- The most-used adherence metric was medication possession ratio (MPR), reported in 51 studies (63%); the next most common was proportion of days covered (PDC) at 11%.
- Quality assessment found 10 high-quality, 59 medium-quality, and 10 low-quality studies; no full economic evaluation was conducted in any included study.
## Methods
- Design: Systematic review conducted according to PRISMA and registered in PROSPERO (CRD42015027338).
- Data/sample: Searches were run in PubMed and Scopus in September 2017, with no publication date or language restrictions; included studies had to report the monetary cost of medication non-adherence for any disease state and provide original data.
- Main analysis: Two reviewers appraised studies using a modified Drummond checklist; costs were converted to 2015 US$, extracted by outcome indicator, and the authors attempted but could not perform a meta-analysis because of heterogeneity and missing statistical parameters.
## Limitations
- The paper states that a meta-analysis could not be performed because of heterogeneity in study design and lack of required statistical parameters, particularly standard deviations.
- The authors note that differences in methodological strategies, adherence definitions, and cost indicators made comparison across studies difficult and limited estimation of the true magnitude of costs.
- Evident from the text: the evidence base was dominated by US studies (66 of 79; 83%), and many studies were partial economic evaluations rather than full economic evaluations, which limits generalisability and comparability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
4 Valid · 0 Not valid · 58 Not checked · 72 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“While Zhao et al80 categorised participants into adherence subgroups, finding that total healthcare costs were lower for the non-adherent population.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Supportedcites [80] Zhao, 2014, Associations between statin adherence level, health care costs, and utilization, J Manag Care Spec Pharm source
The Statistical Analysis section divides participants into statin-adherence groups. The results report that the lowest-adherence group (MPR <40%) had lower estimated total health care costs over one year than every higher-adherence group; the difference was statistically significant for all but the 70%–79% group. This supports the citing sentence’s comparison, although the paper uses a specific low-adherence group rather than a single category of all non-adherent patients. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One study measured the influence of medication non-adherence on direct healthcare costs in metabolic conditions, reporting an unadjusted attributable total cost of $138 525.54”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Partly supportedcites [54] matched to “Association of cinacalcet adherence and costs in patients on dialysis” (2011) sourceExperimental — accuracy not yet measured
The Methods and Results report an analysis of cinacalcet adherence and direct healthcare costs in dialysis patients with secondary hyperparathyroidism, including unadjusted 12-month costs. The Results refer to a table of mean costs, but the values are absent from our copy; no passage verifies the claimed $138,525 unadjusted attributable total cost. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The findings were that, for all levels of non-adherence, costs of non-adherence were higher for Medicare supplemental patients.45”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Partly supportedcites [45] Halpern, 2011, The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis, J Manag Care Pharm sourceExperimental — accuracy not yet measured
The medical-cost results (page unavailable) report higher adjusted costs with low versus high adherence in both groups, with a larger percentage increase in Medicare Advantage patients (18%) than commercial patients (12%). Moderate adherence was also associated with higher costs in the Medicare Advantage group, but not significantly in the commercial group. The claim calls these patients “Medicare supplemental” rather than Medicare Advantage and does not specify that the comparison concerns adjusted percentage increases, so its broader cost comparison is not established. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Seventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted total cost of non-adherence across all disease groups ranged from $949 to $52 341, while the unadjusted total cost ranged from $669 to $162 699.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Medication non-adherence and costs
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
67 more claims
Create a free account to see all 134 claims and every source verdict.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 28
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Medication non-adherence is a widespread problem that causes high costs worldwide [5–10].”
From Medication adherence influencing factors—an (updated) overview of systematic reviews (2019) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, a person-centered approach predicts better outcomes, such as fewer relapses, suicide and overall mortality [91].”
From Therapeutic Adherence of People with Mental Disorders: An Evolutionary Concept Analysis (2023) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“Only then will it be possible to contribute to the improvement of clinical and social outcomes, generate commitment, and guarantee a quality of services that translates into increased adherence rates and reduced number of hospitalizations and all associated costs (including pharmacy costs and inpatient and outpatient costs) [91].”
From Therapeutic Adherence of People with Mental Disorders: An Evolutionary Concept Analysis (2023) · cites this paper as [91]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729 · cited 4×
“The adjusted cost of medication non-adherence was reported in 14 studies with an estimated range of $5271–52 341.(10) 29 31 56 58–60 70 75 76 83 84 86 90 Sokol et al(10) reported the all-cause cost of non-adherence through subgroup analysis of disease states and MPR levels, while Pittman et al(60) reported only using…”
BackgroundMethodInfluentialInterventions for helping patients to follow prescriptions for medications
Haynes, R., McDonald, H., Garg, A., & Montague, P. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011 · Cited by 911
Hess, L. M., Raebel, M. A., Conner, D. A., & Malone, D. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h018 · Cited by 756
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603 · cited 2×
“65 81 98 Six studies used adjusted costs, finding that the total annual cost of non-adherence per patient ranged from $3252 to $19 363.(23) 25 58 59 72 90 Bagalman et al(25) focused primarily on”
BackgroundResult
Cited by
Items 101–200 of 881
Galozy, A., & Nowaczyk, S. (2020) · Journal of Biomedical Informatics · doi:10.1016/j.yjbinx.2020.100075 · Cited by 42
Pedrosa-Naudín, M. A., Gutiérrez-Abejón, E., Herrera-Gómez, F., Fernández-Lázaro, D., & Álvarez, F. J. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122696 · Cited by 31
Foley, L., Hynes, L., Murphy, A. W., & Molloy, G. J. (2021) · British Journal of Health Psychology · doi:10.1111/bjhp.12568 · Cited by 33
Mendibil, X., Tena, G., Duque, A., Uranga, N., Campanero, M. Á., & Alonso, J. M. G. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060907 · Cited by 36
Pike, A. E., Patey, A. M., Lawrence, R., Aubrey‐Bassler, K., Grimshaw, J., Mortazhejri, S., Dowling, S. K., Jasaui, Y., Bhatia, S., Duquettes, D., et al. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01751-6 · Cited by 31
Medication adherence: understanding the issues and finding solutions
While, A. (2020) · British Journal of Community Nursing · doi:10.12968/bjcn.2020.25.10.474 · Cited by 42
Higano, C. S., & Hafron, J. M. (2022) · The Journal of Urology · doi:10.1097/ju.0000000000003081 · Cited by 39
Racial Disparities in Medication Adherence Barriers: Pediatric Epilepsy as an Exemplar
Gutierrez‐Colina, A. M., Wetter, S. E., Mara, C. A., Guilfoyle, S. M., & Modi, A. C. (2022) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsac001 · Cited by 30
Cutler, R. L., Torres-Robles, A., Wiecek, E., Drake, B., van der Linden, N., Benrimoj, S. I., & García‐Cárdenas, V. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s191482 · Cited by 56
Self-citationKardas, P., Bago, M., Barnestein‐Fonseca, P., Garuolienè, K., Granås, A. G., Gregório, J., Hadžiabdić, M. O., Vaňková, B., Leiva-Fernández, F., Lewek, P., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944829 · Cited by 32
Model-Based Design of Closed Loop Deep Brain Stimulation Controller using Reinforcement Learning
Gao, Q., Naumann, M., Jovanov, I., Lesi, V., Kamaravelu, K., Grill, W. M., & Pajić, M. (2020) · ACM/IEEE International Conference on Cyber-Physical Systems (ICCPS) · doi:10.1109/iccps48487.2020.00018 · Cited by 43
Gil-Guillén, V. F., Balsa, A., Bernárdez, B., y Llorca, C. V., Contreras, E. M., de la Haba-Rodríguez, J., Castellano, J. M., & Martínez, J. C. G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph191912036 · Cited by 40
Gauthier‐Loiselle, M., Cloutier, M., Toro, W., Patel, A. A., Shi, S., Davidson, M., Bischof, M., LaMarca, N. M., & Dabbous, O. H. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01938-w · Cited by 28
Novel application of approaches to predicting medication adherence using medical claims data
Zullig, L. L., Jazowski, S. A., Wang, T. Y., Hellkamp, A. S., WOJDYLA, D. M., Thomas, L. E., Egbuonu‐Davis, L., Beal, A. C., & Bosworth, H. B. (2019) · Health Services Research · doi:10.1111/1475-6773.13200 · Cited by 36
The doctor’s digital double: how warmth, competence, and animation promote adherence intention
Dai, Z., & MacDorman, K. F. (2018) · PeerJ Computer Science · doi:10.7717/peerj-cs.168 · Cited by 33
Dashputre, A. A., Gatwood, K. S., & Gatwood, J. D. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.2.186 · Cited by 27
Determinants of Non-Adherence to the Medications for Dyslipidemia: A Systematic Review
Lopes, J., & Santos, P. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s319604 · Cited by 38
Setayeshgar, S., Kingwell, E., Zhu, F., Zhang, T., Carruthers, R. L., Marrie, R. A., Evans, C. D., & Tremlett, H. L. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.11.004 · Cited by 28
Factors Affecting the Adherence to Disease-Modifying Therapy in Patients With Multiple Sclerosis
Dallı, Ö. E., Yeşilbalkan, Ö. U., & Yüceyar, N. (2018) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0000000000000395 · Cited by 29
Key Features of Smart Medication Adherence Products: Updated Scoping Review
Faisal, S., Samoth, D., Aslam, Y., Patel, H., Park, S., Baby, B., & Patel, T. (2023) · JMIR Aging · doi:10.2196/50990 · Cited by 36
Jacob, V., Reynolds, J. A., Chattopadhyay, S. K., Hopkins, D. P., Therrien, N. L., Jones, C. D., Durthaler, J. M., Rask, K. J., Cuellar, A. E., Clymer, J. M., et al. (2021) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.08.021 · Cited by 34
Seixas, A. A., Connors, C., Chung, A., Donley, T., & Jean‐Louis, G. (2020) · JMIR mhealth and uhealth · doi:10.2196/16429 · Cited by 34
Atolagbe, E. T., Sivanandy, P., & Ingle, P. V. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1132489 · Cited by 37
Novel formulations of oral bisphosphonates in the treatment of osteoporosis
Fuggle, N. R., Al‐Daghri, N. M., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M. P. T., Giusti, A., et al. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02272-z · Cited by 31
Robinson, L., Arden, M. A., Dawson, S., Walters, S. J., Wildman, M. J., & Stevenson, M. (2022) · Health Psychology Review · doi:10.1080/17437199.2022.2034516 · Cited by 33
Clinical and economic consequences of medication nonadherence: a review of systematic reviews
Achterbosch, M., Aksoy, N., Obeng, G. D., Ameyaw, D., Ágh, T., & van Boven, J. F. M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1570359 · Cited by 49
Žeželj, I. L., Petrović, M., Ivanović, A., & Kurčubić, P. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279122 · Cited by 31
Patel, T., Ivo, J., Pitre, T., Faisal, S., Antunes, K., & Oda, K. (2022) · JMIR Formative Research · doi:10.2196/34906 · Cited by 33
Adherence to treatment in allergic respiratory diseases
Baiardini, I., Novakova, S. M., Mihaicuta, S. D., Oğuzülgen, İ. K., & Canonica, G. W. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1554438 · Cited by 34
Medication Adherence in Cancer Patients: A Comprehensive Review
Reshma, V., Chacko, A. M., Abdulla, N. H., Annamalai, M., & Kandi, V. (2024) · Cureus · doi:10.7759/cureus.52721 · Cited by 69
Statistical considerations for medication adherence research
DeClercq, J., & Choi, L. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1793312 · Cited by 27
Soft robot-enabled controlled release of oral drug formulations
Huang, H., Lyu, Y., & Nan, K. (2023) · Soft Matter · doi:10.1039/d2sm01624a · Cited by 27
Clinical standards for drug-susceptible pulmonary TB
Akkerman, O. W., Duarte, R., Tiberi, S., Schaaf, H. S., Lange, C. G., Alffenaar, J. C., Denholm, J. T., Carvalho, A. C. C., Bolhuis, M. S., Borisov, S. E., et al. (2022) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.22.0228 · Cited by 26
Kanyongo, W., & Ezugwu, A. E.-S. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101210 · Cited by 35
Hassan, T. A., Sáenz, J. E., Dučinskienė, D., Cook, J. P., Imperato, J., & Zou, K. H. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s313626 · Cited by 32
Al‐Noumani, H., Alharrasi, M., José, J., Al‐Naamani, Z., & Panchatcharam, S. M. (2021) · Clinical Nursing Research · doi:10.1177/10547738211033754 · Cited by 33
Onyekaonwu, C. B., Peter-Anyebe, A. C., & Raphael, F. O. (2019) · International Journal of Scientific Research in Science and Technology · doi:10.32628/ijsrst52310387 · Cited by 32
Stecher, C. D., Mukasa, B., & Linnemayr, S. (2020) · Journal of Health Economics · doi:10.1016/j.jhealeco.2021.102443 · Cited by 25
Farhana, L., Rahayu, F. P., Sholihah, S., Sweileh, W. M., Abdulah, R., & Alfian, S. D. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s530503 · Cited by 41
Scales for assessing medication adherence in patients with hypertension
Chatziefstratiou, A. A., Giakoumidakis, K., Fotos, N. V., Baltopoulos, G. J., & Brokalaki, H. (2019) · British Journal of Nursing · doi:10.12968/bjon.2019.28.21.1388 · Cited by 20
Ali, M., Grogan, S., Powell, S., Staniford, L. J., Nazir, J., Landeira, M., Covernton, P. J. O., Jaggi, A., Fatoye, F., & Holt, M. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01098-y · Cited by 28
What Are the Factors Associated with Nonadherence to Medications in Patients with Chronic Diseases?
Bawab, A. Q. A., Al-Qerem, W. A., Abusara, O. H., Alkhatib, N. S., Mansour, M., & Horne, R. (2021) · Healthcare · doi:10.3390/healthcare9091237 · Cited by 35
Mate, K., Engler, K., Lessard, D., & Lebouché, B. (2023) · International Journal of STD & AIDS · doi:10.1177/09564624231169329 · Cited by 33
Li, L., Wang, Z., Cui, L., Xu, Y., Lee, H., & Guan, K. (2023) · World Allergy Organization Journal · doi:10.1016/j.waojou.2022.100739 · Cited by 23
Lu, K., Xiong, X., Brown, J., Horras, A., Yuan, J., & Li, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706289 · Cited by 27
Levy, R. M., Mekhail, N. A., Kapural, L., Gilmore, C. A., Petersen, E., Goree, J. H., Pope, J. E., Costandi, S. J., Kallewaard, J. W., Thomson, S., et al. (2024) · Neuromodulation Technology at the Neural Interface · doi:10.1016/j.neurom.2024.07.003 · Cited by 28
Tonin, F. S., Wiecek, E., Torres-Robles, A., Pontarolo, R., Benrimoj, S. I., Fernández-Llimós, F., & García‐Cárdenas, V. (2018) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2018.05.010 · Cited by 23
Telepharmacy in oncology care: A scoping review
Vo, A. T., & Gustafson, D. L. (2020) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x20975257 · Cited by 22
Andreae, S. J., Andreae, L. J., Cherrington, A., Richman, J., Johnson, E., Clark, D., & Safford, M. M. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106358 · Cited by 23
Qadus, S., Naser, A. Y., Ofori‐Asenso, R., Ademi, Z., Awawdeh, S. A., & Liew, D. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00553-6 · Cited by 31
Tibble, H., Flook, M., Sheikh, A., Tsanas, A., Horne, R., Vrijens, B., Geest, S. D., & Stagg, H. R. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14458 · Cited by 28
Bott, D., Subramanian, A., Edgar, D. F., Lawrenson, J. G., & Campbell, P. (2023) · Ophthalmic and Physiological Optics · doi:10.1111/opo.13245 · Cited by 29
Prevalence and predictors of primary nonadherence to medications prescribed in primary care
Zeitouny, S., Cheng, L., Wong, S. T., Tadrous, M., McGrail, K. M., & Law, M. R. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.221018 · Cited by 31
Kherallah, R. Y., Rifai, M. A., Kamat, I., Krittanawong, C., Mahtta, D., Lee, M., Liu, J., Nasir, K., Elizondo, J. V., Patel, J., et al. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106715 · Cited by 25
Ratzki‐Leewing, A. A., Ryan, B. L., Buchenberger, J. D., Dickens, J. W., Black, J. E., & Harris, S. B. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049782 · Cited by 25
A data-driven typology of asthma medication adherence using cluster analysis
Tibble, H., Chan, A. H. Y., Mitchell, E. A., Horne, E. M. F., Doudesis, D., Horne, R., Mizani, M. A., Sheikh, A., & Tsanas, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-72060-0 · Cited by 24
Lafata, J. E., Nguyen, B., Staresinic, C., Johnson, M., Gratie, D., & Muluneh, B. (2022) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211073576 · Cited by 24
Strike, K., Chan, A. K. C., Iorio, A., Maly, M. R., Stratford, P. W., & Solomon, P. E. (2020) · The Journal of Haemophilia Practice · doi:10.17225/jhp00152 · Cited by 21
Oliveira, H. C., Neto, D. H., Carvalho, S. D. L., de Barros, R. D. C. L., Neves, M. L. D. S., Andrechuk, C. R. S., Alexandre, N. M. C., Ribeiro, P. A. B., & Rodrigues, R. C. M. (2023) · Systematic Reviews · doi:10.1186/s13643-023-02340-z · Cited by 31
Home Care Patients’ Experiences with Home Care Nurses’ Support in Medication Adherence
Dijkstra, N. E., Vervloet, M., Sino, C. G. M., Heerdink, E. R., Nelissen-Vrancken, M. H. J. M. G., Bleijenberg, N., de Bruin, M., & Schoonhoven, L. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s302818 · Cited by 25
Kardas, P., Cieszyński, J., Czech, M., Banaś, I., & Lewek, P. (2019) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.14994 · Cited by 21
Ágh, T., Hadžiabdić, M. O., Garuolienè, K., Granås, A. G., Aarnio, E., Menditto, E., Gregório, J., Barnestein‐Fonseca, P., Mevsim, V., Kardas, P., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.892240 · Cited by 25
Medication Adherence Among Patients with Advanced Prostate Cancer Using Oral Therapies
Pilon, D., LaMori, J. C., Rossi, C., Durkin, M., Ghelerter, I., Ke, X., Lafeuille, M., Ellis, L., & Lefèbvre, P. (2021) · Future Oncology · doi:10.2217/fon-2021-0992 · Cited by 21
People-centered care and patients' beliefs about medicines and adherence: A cross-sectional study
Dilles, T., Mortelmans, L., Loots, E., Sabbe, K., Feyen, H., Wauters, M., Haegdorens, F., & Baetselier, E. D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e15795 · Cited by 20
Ágh, T., Hiligsmann, M., Borah, B. J., Beaudart, C., Turcu-Ştiolică, A., Manias, E., Jakab, I., Pednekar, P. P., Zeber, J. E., & Peterson, A. M. (2023) · Value in Health · doi:10.1016/j.jval.2023.10.016 · Cited by 21
Turcu-Ştiolică, A., Subtirelu, M.-S., Ciurea, P. L., Dinescu, Ș. C., Bogdán, M., Bărbulescu, A. L., Glavan, D.-G., Turcu-Stiolica, R.-A., Firulescu, S. C., Chisălau, B. A., et al. (2020) · Medicina · doi:10.3390/medicina56040178 · Cited by 22
How to balance valuable innovation with affordable access to medicines in Belgium?
Simoens, S., Abdallah, K., Barbier, L., Lacosta, T. B., Blonda, A. M., Car, E., Claessens, Z., Desmet, T., Sutter, E. D., Govaerts, L., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.960701 · Cited by 22
Optimizing Social Support in Oncology with Digital Platforms
Katsaros, D., Hawthorne, J., Patel, J., Pothier, K., Aungst, T. D., & Franzese, C. (2022) · JMIR Cancer · doi:10.2196/36258 · Cited by 25
Anakwa, N. O., Teye‐Kwadjo, E., & Kretchy, I. A. (2021) · Nursing Open · doi:10.1002/nop2.797 · Cited by 26
Ali, E. E., Chan, S. S. L., Poh, H. Y., Susanto, Y. A., Suganya, T., Leow, J. L., Pang, C. K., Chew, L. S. T., & Yap, K. Y. (2019) · Journal of Medical Systems · doi:10.1007/s10916-019-1168-x · Cited by 20
Faisal, S., Ivo, J., Lee, C., Carter, C., & Patel, T. (2020) · Journal of Pharmacy Practice · doi:10.1177/0897190020977756 · Cited by 18
Habib, B., Buckeridge, D. L., Bustillo, M., Marquez, S. N., Thakur, M., Tran, T., Weir, D. L., & Tamblyn, R. M. (2021) · JAMIA Open · doi:10.1093/jamiaopen/ooab050 · Cited by 21
Scime, N. V., Metcalfe, A., Nettel‐Aguirre, A., Tough, S., & Chaput, K. H. (2023) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14516 · Cited by 19
Factors Influencing Compliance to Follow-up Visits in Orthopaedic Surgery
Bender, M., Jain, N., Giron, A., Harder, J. G., Rounds, A. D., & MacKay, B. J. (2024) · JAAOS Global Research and Reviews · doi:10.5435/jaaosglobal-d-23-00140 · Cited by 26
Skladaný, Ľ., Vnenčáková, J., Lafférs, L., Škvarková, B., Hrubá, E., Molčan, P., & Koller, T. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s283034 · Cited by 21
Patient Perspective on Iron Chelation Therapy: Barriers and Facilitators of Medication Adherence
Chong, C. C., Redzuan, A. M., Sathar, J., & Makmor‐Bakry, M. (2021) · Journal of Patient Experience · doi:10.1177/2374373521996958 · Cited by 23
Challenges in Improving Adherence to Diet and Drug Treatment in Hypercholesterolemia Patients
Baratta, F., Angelico, F., & Ben, M. D. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20105878 · Cited by 24
García‐Pérez, L., Linertová, R., Serrano-Pérez, P., Trujillo‐Martín, M. M., Rodríguez‐Rodríguez, L., Valcárcel‐Nazco, C., & del Pino‐Sedeño, T. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1782434 · Cited by 20
A decision-neuroscientific intervention to improve cognitive recovery after stroke
Studer, B., Timm, A., Sahakian, B. J., Kalenscher, T., & Knecht, S. (2021) · Brain · doi:10.1093/brain/awab128 · Cited by 25
Lee, J. S., Escano, R. S., Therrien, N. L., Kumar, A., Bhatt, A., Pollack, L. M., Jackson, S. L., & Luo, F. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.037357 · Cited by 33
Xu, D. R., Gong, W., Gloyd, S., Caine, E. D., Simoni, J. M., Hughes, J. P., Xiao, S., He, W., Dai, B., Lin, M., et al. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.05.014 · Cited by 18
A Systematic Review Uncovering Modifiable Influences on Statin Adherence
Rosenberg, J., Lampridou, S., Moores, A., Garfield, S., Wingfield, D., & Judah, G. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s502645 · Cited by 21
Le, T., & Orge, F. H. (2022) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2022.08.003 · Cited by 20
Okasha, T. A., Radwan, D. N., Elkholy, H. A., Hendawy, H., Shourab, E. M. M. E., Teama, R., & Abdelgawad, A. S. (2020) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v26i0.1437 · Cited by 22
Zhu, Z., Roy, D., Feng, S., & Vogler, B. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.11.006 · Cited by 23
Fowler, J. C., Cope, N., Knights, J., Phiri, P., Makin, A., Peters-Strickland, T., & Rathod, S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-025952 · Cited by 20
Yong, P. J., Alsowayan, N., Noga, H. L., Williams, C., Allaire, C., Lisonkova, S., & Bedaiwy, M. A. (2020) · Human Reproduction Open · doi:10.1093/hropen/hoz040 · Cited by 19
Bailey, S. C., Wallia, A., Wright, S., Wismer, G. A., Infanzon, A. C., Curtis, L. M., Brokenshire, S. A., Chung, A. E., Reuland, D. S., Hahr, A. J., et al. (2019) · Journal of Medical Internet Research · doi:10.2196/13499 · Cited by 15
Thirunavukkarasu, A., Alshahrani, A. N. A., Abdel-Salam, D. M., Alhazmi, A., ALruwaili, B. F., Alsaidan, A. A., Narapureddy, B. R., AL-Ruwaili, A. M., aljabri, F. G., Albalawi, R. K., et al. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s388365 · Cited by 31
Faisal, S., Ivo, J., Tennant, R., Prior, K.-A., Grindrod, K., McMillan, C., & Patel, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262012 · Cited by 20
Lazarević, L. B., Knežević, G., Purić, D., Teovanović, P., Petrović, M., Ninković, M., Živanović, M., Stanković, S., Branković, M., Lukić, P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41243-w · Cited by 24
Tolley, A., Grewal, K., Weiler, A., Papameletiou, A. M., Hassan, R., & Basu, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1183818 · Cited by 21
Morgan, M., Anderson, R., Walburn, J., Weinman, J. A., & Sarkany, R. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024445 · Cited by 16
Medication Adherence Prediction Through Online Social Forums: A Case Study of Fibromyalgia
Haas, K., Miled, Z. B., & Mahoui, M. (2019) · JMIR Medical Informatics · doi:10.2196/12561 · Cited by 18
Ghorbani, H., Chalabyan, A., Minasyan, A., Ghorbani, P., Wood, D. A., Ghorbani, S., Yeremyan, R., Manasyan, A., & Zehra, F. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-09997-0 · Cited by 17
Medication adherence: A method for designing context-aware reminders
Singh, N., & Varshney, U. (2019) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2019.103980 · Cited by 21
Ownby, R. L., Waldrop‐Valverde, D., Davenport, R., Simonson, M. R., Caballero, J., Purcell, D. J., Purcell, D. J., Ayala, V., González, J., Patel, N., et al. (2024) · Journal of Ageing and Longevity · doi:10.3390/jal4020005 · Cited by 20
Metadata
- Authors
- Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V.
- Affiliations
- University of Technology Sydney (AU)
- Department of Social Pharmacy Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), University of Lisbon, Lisbon, Portugal
- The University of Sydney (AU)
- Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia
- Corresponding author
- Cutler, Rachelle Louise
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2018-01
- Volume
- 8
- Issue
- 1
- Pages
- e016982
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5780689
- OpenAlex
- W2790318238
- Cited by
- 900
- References
- 113
- Citations by year
- 2026: 83 · 2025: 111 · 2024: 159 · 2023: 134 · 2022: 112 · 2021: 124 · 2020: 91 · 2019: 68 · 2018: 16
- FWCI
- 16.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OPUS - Open Publications of UTS Scholars (University of Technology Sydney) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Australian Government
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- medication non-adherence, economic burden, health care costs, medication possession ratio, adherence measurement, health policy
- MeSH terms
- Cost-Benefit Analysis, Disease, Drug Therapy, Humans, Drug Monitoring, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.